Inhibition of Platelet Aggregation by "Brilinta"(Ticagrelor)
ApprovedCompleted 0 watching 0 views this week🔥 Hot
85
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Stable Coronary Heart Disease (CHD)
Conditions
Stable Coronary Heart Disease (CHD)
Trial Timeline
Feb 1, 2014 → Nov 1, 2014
NCT ID
NCT02064985About Inhibition of Platelet Aggregation by "Brilinta"(Ticagrelor)
Inhibition of Platelet Aggregation by "Brilinta"(Ticagrelor) is a approved stage product being developed by AstraZeneca for Stable Coronary Heart Disease (CHD). The current trial status is completed. This product is registered under clinical trial identifier NCT02064985. Target conditions include Stable Coronary Heart Disease (CHD).
Hype Score Breakdown
Clinical
30
Activity
20
Company
10
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02064985 | Approved | Completed |
Competing Products
20 competing products in Stable Coronary Heart Disease (CHD)
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| eFT508 + Avelumab | eFFECTOR Therapeutics | Phase 2 | 44 |
| Atorvastatin 20mg loading + Atorvastatin 80mg loading | Yuhan | Approved | 85 |
| ASP7991 | Astellas Pharma | Phase 1 | 33 |
| Epoetin Alfa + Roxadustat | Astellas Pharma | Phase 3 | 77 |
| TRC041266 + Placebo | Torrent Pharmaceuticals | Phase 3 | 77 |
| Evorpacept (ALX148) + Cetuximab + Pembrolizumab | Eli Lilly | Phase 2 | 52 |
| budesonide/formoterol + formoterol | AstraZeneca | Phase 2 | 52 |
| Ticagrelor + Clopidogrel + Aspirin | AstraZeneca | Phase 2 | 52 |
| TC-5214 + Placebo | AstraZeneca | Phase 1 | 33 |
| ticagrelor + clopidogrel | AstraZeneca | Phase 2 | 52 |
| Ticagrelor + Clopidogrel | AstraZeneca | Approved | 85 |
| Ticagrelor + Clopidogrel | AstraZeneca | Approved | 85 |
| grapiprant + grapiprant and pembrolizumab | Merck | Phase 1 | 33 |
| Bevacizumab + Capecitabine + Pembrolizumab | Merck | Phase 2 | 52 |
| Nicorandil + Standard Treatment | Merck | Approved | 85 |
| BPS804 + Placebo | Novartis | Phase 2 | 52 |
| CLR325 | Novartis | Phase 2 | 52 |
| Erenumab + Placebo | Amgen | Phase 2 | 51 |
| Ranolazine + Placebo | Gilead Sciences | Approved | 84 |
| ranolazine + placebo | Gilead Sciences | Approved | 84 |